Background: In countries where frontline drug approval is limited to first-generation proteasome inhibitors or immunomodulatory drugs, relapses have been both more frequent and less durable. We investigated real world data on the efficacy and safety of daratumumab monotherapy among patients with relapsed refractory multiple myeloma (RRMM) from Turkey using a prospective early access program.
Patients And Methods: A total of 42 patients with RRMM after a minimum of 3 previous lines of proteasome inhibitor/immunomodulatory drug-based treatments were included from 25 centers across Turkey. Daratumumab monotherapy was administered intravenously at a dose of 16 mg/kg weekly (cycles 1-2), on alternate weeks (cycles 3-6), and monthly thereafter.
Results: The median daratumumab monotherapy duration was 5.5 months (range, 0.2-28.7 months). The overall response rate was 45.2%, including 14 (33.3%) partial responses, 4 (9.5%) very good partial responses, and 1 (2.4%) complete response. The median duration of response was 4.9 months. The median progression-free survival (PFS) was 5.5 (95% confidence interval, 2.6-8.4 months) with 12- and 18-month PFS rates of 35.7% and 31.0%, respectively. The median overall survival was not reached; the 12- and 18-month overall survival rates were 64.3% and 59.5%, respectively. The depth of response had a significant effect on PFS (log-rank test, P = .026). Overall, of the 76 adverse events reported, 33 (43.4%) were grade ≥ 3; only 4 (9.52%) were grade 3 infusion-related reactions. No infusion-related reactions or adverse events led to treatment discontinuation.
Conclusion: The present findings from our daratumumab early access program have confirmed the efficacy and safety profile of daratumumab monotherapy in heavily pretreated Turkish patients with RRMM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2020.02.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Effectiveness and Safety of Intravenous Daratumumab in Patients with Multiple Myeloma: A Multicenter, Observational Study from Korea.
Cancer Res Treat
December 2024
Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Purpose: Daratumumab is a novel, first-in-class monoclonal antibody approved for use as monotherapy and in combination with other treatments for patients with multiple myeloma (MM). The aim of this observational study was to evaluate the effectiveness and safety of daratumumab in real-world clinical practice.
Materials And Methods: This observational multicenter study collected data from patients with MM treated in Korea between June 1, 2018, and February 28, 2022.
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
N Engl J Med
December 2024
From Alexandra General Hospital, National and Kapodistrian University of Athens, Athens (M.A.D.); Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC (P.M.V.); Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo (F.S.); Tel-Aviv Sourasky (Ichilov) Medical Center and Tel Aviv University, Tel Aviv, Israel (Y.C.C.); Clínica Medica São Germano, São Paulo (V.H.); Cross Cancer Institute, University of Alberta, Edmonton, Canada (I. Sandhu); Kent and Canterbury Hospital, Canterbury, United Kingdom (J.L.); Perth Blood Institute, Murdoch University, Perth, WA, Australia (R.I.B.); Japanese Red Cross Medical Center, Tokyo (K.S.); Ogaki Municipal Hospital, Ogaki City, Japan (H.K.); Albert Schweitzer Hospital, Dordrecht, the Netherlands (M.-D.L.); Ankara University, Ankara, Turkey (M.B.); Washington University School of Medicine, St. Louis (K.S.-G.); Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona (A.O.); South Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary (G.M.); Hospital Alemán, Buenos Aires (G.G.); Jessa Hospital, Hasselt, Belgium (K.T.); Charles University and General Hospital, Prague, Czech Republic (I. Spicka); Rigshospitalet, University of Copenhagen, Copenhagen (A.K.M.); SSD Clinical Trials in Oncol-ematologia e Mieloma Multiplo, AOU Città della Salute e della Scienza di Torino, Turin, Italy (S.B.); Medical Unit Hematology, Karolinska University Hospital, Stockholm (K.U.); Institute of Hematology and Transfusion Medicine, Warsaw, Poland (B.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M.); University of Washington and Fred Hutchinson Cancer Center, Seattle (A.J.C.); University Hospital Hôtel-Dieu, Nantes, France (P.M.); University Hospital of Salamanca, IBSAL, and Cancer Research Center, IBMCC, Salamanca, Spain (M.-V.M.); GMMG Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany (H.G.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Shanghai, China (L.S., L.L.); Janssen Scientific Affairs, Horsham, PA (A.C.); Janssen Research and Development, Raritan, NJ (E.G.K., R.M.D.); Janssen Research and Development, Beerse, Belgium (E.R.); Janssen Research and Development, Spring House, PA (R.C.); and Mayo Clinic, Rochester, MN (S.V.R.).
Background: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor disease of active multiple myeloma for which no treatments have been approved.
Methods: In this phase 3 trial, we randomly assigned patients with high-risk smoldering multiple myeloma to receive either subcutaneous daratumumab monotherapy or active monitoring.
Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study.
Transplant Cell Ther
November 2024
Catholic Research Network for Multiple Myeloma, Republic of Korea; Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Although bispecific T-cell engager (BiTE) is a promising treatment for relapsed/refractory multiple myeloma (RRMM), it needs to be evaluated in a real-world setting. This study aimed to evaluate the efficacy and safety of BiTEs compared with a synthetic standard of care (SOC). From a multicenter registry database of 474 patients with RRMM who received third- or more advanced-line treatments between January 2021 and October 2023, 1:1 propensity score-matched BiTE cohort (n = 71) and SOC cohort (n = 71) were established.
View Article and Find Full Text PDFCase report: A case of proliferative glomerulonephritis with monoclonal kappa-light chain deposits treated with daratumumab combination therapy.
Front Med (Lausanne)
October 2024
Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Article Synopsis
- Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a kidney disease associated with monoclonal gammopathy, primarily involving IgG, and the study focuses on a rare variant known as PGNMID-LC, which involves only light chains.
- A new treatment regimen called D-VCd, which combines daratumumab with other drugs, was implemented for a patient with PGNMID-LC, resulting in significant improvement in their symptoms and laboratory results.
- The findings suggest that the D-VCd regimen could be effective for PGNMID-LC by targeting tumor clonality, but more clinical trials are needed to validate these results due to the limited data
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!